We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Canopy Growth Corporation (CGC) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Canopy Growth Corporation (CGC - Free Report) ended the recent trading session at $1.08, demonstrating a +2.86% change from the preceding day's closing price. This change outpaced the S&P 500's 1.02% gain on the day. Elsewhere, the Dow saw an upswing of 0.63%, while the tech-heavy Nasdaq appreciated by 1.23%.
Shares of the company have appreciated by 2.94% over the course of the past month, outperforming the Medical sector's loss of 4.81%, and the S&P 500's gain of 0.63%.
The upcoming earnings release of Canopy Growth Corporation will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$0.06, reflecting a 93.62% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $53.26 million, showing a 17.56% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.36 per share and revenue of $210.58 million, indicating changes of +87.92% and +8.94%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 24.14% higher within the past month. Canopy Growth Corporation presently features a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 158, this industry ranks in the bottom 36% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Canopy Growth Corporation (CGC) Beats Stock Market Upswing: What Investors Need to Know
Canopy Growth Corporation (CGC - Free Report) ended the recent trading session at $1.08, demonstrating a +2.86% change from the preceding day's closing price. This change outpaced the S&P 500's 1.02% gain on the day. Elsewhere, the Dow saw an upswing of 0.63%, while the tech-heavy Nasdaq appreciated by 1.23%.
Shares of the company have appreciated by 2.94% over the course of the past month, outperforming the Medical sector's loss of 4.81%, and the S&P 500's gain of 0.63%.
The upcoming earnings release of Canopy Growth Corporation will be of great interest to investors. The company's earnings per share (EPS) are projected to be -$0.06, reflecting a 93.62% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $53.26 million, showing a 17.56% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.36 per share and revenue of $210.58 million, indicating changes of +87.92% and +8.94%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 24.14% higher within the past month. Canopy Growth Corporation presently features a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 158, this industry ranks in the bottom 36% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.